Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2022

Open Access 01-12-2022 | Lung Cancer | Review

IDO/kynurenine pathway in cancer: possible therapeutic approaches

Author: Eslam E. Abd El-Fattah

Published in: Journal of Translational Medicine | Issue 1/2022

Login to get access

Abstract

Cancer is one of the leading causes of death in both men and women worldwide. One of the main changes associated with cancer progression, metastasis, recurrence, and chemoresistance is the change in the tumor immune microenvironment, especially immunosuppression. Cancer immunosuppression appears in multiple forms, such as inhibition of immuno-stimulant cells with downregulation of immuno-stimulant mediators or through stimulation of immuno-suppressive cells with upregulation of immunosuppressive mediators. One of the most immunosuppressive mediators that approved potency in lung cancer progression is indoleamine 2,3-dioxygenase (IDO) and its metabolite kynurenine (Kyn). The current review tries to elucidate the role of IDO/Kyn on cancer proliferation, apoptosis, angiogenesis, oxidative stress, and cancer stemness. Besides, our review investigates the new therapeutic modalities that target IDO/Kyn pathway and thus as drug candidates for targeting lung cancer and drugs that potentiate IDO/Kyn pathway and thus can be cancer-promoting agents.
Literature
1.
Larkin PB, Sathyasaikumar KV, Notarangelo FM, Funakoshi H, Nakamura T, Schwarcz R, et al. Tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase 1 make separate, tissue-specific contributions to basal and inflammation-induced kynurenine pathway metabolism in mice. Biochem Biophys Acta. 2016;1860(11 Pt A):2345–54.PubMedCrossRef
2.
Abd El-Fattah EE, Abdelhamid AM. Benzo[a]pyrene immunogenetics and immune archetype reprogramming of lung. Toxicology. 2021;463: 152994.PubMedCrossRef
3.
Badawy AAB, Guillemin G. The plasma [kynurenine]/[tryptophan] ratio and indoleamine 2,3-dioxygenase: time for appraisal. Int J Tryptophan Res. 2019;12:1178646919868978.PubMedPubMedCentralCrossRef
4.
Tang D, Yue L, Yao R, Zhou L, Yang Y, Lu L, et al. P53 prevent tumor invasion and metastasis by down-regulating IDO in lung cancer. Oncotarget. 2017;8(33):54548–57.PubMedPubMedCentralCrossRef
5.
Riess C, Schneider B, Kehnscherper H, Gesche J, Irmscher N, Shokraie F, et al. Activation of the kynurenine pathway in human malignancies can be suppressed by the cyclin-dependent kinase inhibitor dinaciclib. Front Immunol. 2020;11:55.PubMedPubMedCentralCrossRef
6.
Richard DM, Dawes MA, Mathias CW, Acheson A, Hill-Kapturczak N, Dougherty DM. L-tryptophan: basic metabolic functions, behavioral research and therapeutic indications. Int J Tryptophan Res. 2009;2:45–60.PubMedPubMedCentralCrossRef
7.
Milburn DS, Myers CW. Tryptophan toxicity: a pharmacoepidemiologic review of eosinophilia-myalgia syndrome. DICP Ann Pharmacother. 1991;25(11):1259–62.
8.
Zhai L, Bell A, Ladomersky E, Lauing KL, Bollu L, Sosman JA, et al. Immunosuppressive IDO in cancer: mechanisms of action, animal models, and targeting strategies. Front Immunol. 2020;11:1185.PubMedPubMedCentralCrossRef
9.
Jiang X, Xu L, Tang L, Liu F, Chen Z, Zhang J, et al. Role of the indoleamine-2,3-dioxygenase/kynurenine pathway of tryptophan metabolism in behavioral alterations in a hepatic encephalopathy rat model. J Neuroinflamm. 2018;15(1):3.CrossRef
10.
Platten M, von Knebel DN, Oezen I, Wick W, Ochs K. Cancer immunotherapy by targeting IDO1/TDO and their downstream effectors. Front Immunol. 2014;5:673.PubMed
11.
El-Ashmawy NE, Salem ML, Abd El-Fattah EE, Khedr EG. Targeting CD166+ lung cancer stem cells: molecular study using murine dendritic cell vaccine. Toxicol Appl Pharmacol. 2021;429: 115699.PubMedCrossRef
12.
Dey S, Mondal A, DuHadaway JB. IDO1 Signaling through GCN2 in a subpopulation of Gr-1(+) cells shifts the IFNγ/IL6 balance to promote neovascularization IDO1-dependent vascularizing cells at the IFNγ/IL6 interface. Cancer Immunol Res. 2021;9(5):514–28.PubMedCrossRef
13.
Munn DH, Sharma MD, Baban B, Harding HP, Zhang Y, Ron D, et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity. 2005;22(5):633–42.PubMedCrossRef
14.
Pertovaara M, Heliövaara M, Raitala A, Oja SS, Knekt P, Hurme M. The activity of the immunoregulatory enzyme indoleamine 2,3-dioxygenase is decreased in smokers. Clin Exp Immunol. 2006;145(3):469–73.PubMedPubMedCentralCrossRef
15.
Jiang X, Lin Q, Xu L, Chen Z, Yan Q, Chen L, et al. Indoleamine-2,3-dioxygenase mediates emotional deficits by the kynurenine/tryptophan pathway in the ethanol addiction/withdrawal mouse model. Front Cell Neurosci. 2020;14:11.PubMedPubMedCentralCrossRef
16.
Salem ML, El-Ashmawy NE, Abd El-Fattah EE, Khedr EG. Immunosuppressive role of Benzo[a]pyrene in induction of lung cancer in mice. Chem Biol Interact. 2021;333: 109330.PubMedCrossRef
17.
Georganaki M, Ramachandran M, Tuit S, Núñez NG, Karampatzakis A, Fotaki G, et al. Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy. Oncoimmunology. 2020;9(1):1730538.PubMedPubMedCentralCrossRef
18.
Ala M. The footprint of kynurenine pathway in every cancer: a new target for chemotherapy. Eur J Pharmacol. 2021;896: 173921.PubMedCrossRef
19.
Merlo LMF, DuHadaway JB, Montgomery JD, Peng W-D, Murray PJ, Prendergast GC, et al. Differential roles of IDO1 and IDO2 in T and B cell inflammatory immune responses. Front Immunol. 2020;11:1861.PubMedPubMedCentralCrossRef
20.
Ball HJ, Yuasa HJ, Austin CJD, Weiser S, Hunt NH. Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway. Int J Biochem Cell Biol. 2009;41(3):467–71.PubMedCrossRef
21.
Li P, Xu W, Liu F, Zhu H, Zhang L, Ding Z, et al. The emerging roles of IDO2 in cancer and its potential as a therapeutic target. Biomed Pharmacother. 2021;137: 111295.PubMedCrossRef
22.
Michels H, Seinstra RI, Uitdehaag JC, Koopman M, van Faassen M, Martineau CN, et al. Identification of an evolutionary conserved structural loop that is required for the enzymatic and biological function of tryptophan 2,3-dioxygenase. Sci Rep. 2016;6:39199.PubMedPubMedCentralCrossRef
23.
Onesti CE, Boemer F, Josse C, Leduc S, Bours V, Jerusalem G. Tryptophan catabolism increases in breast cancer patients compared to healthy controls without affecting the cancer outcome or response to chemotherapy. J Transl Med. 2019;17(1):239.PubMedPubMedCentralCrossRef
24.
Suzuki Y, Suda T, Furuhashi K, Suzuki M, Fujie M, Hahimoto D, et al. Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer. Lung Cancer. 2010;67(3):361–5.PubMedCrossRef
25.
Wang S, Wu J, Shen H, Wang J. The prognostic value of IDO expression in solid tumors: a systematic review and meta-analysis. BMC Cancer. 2020;20(1):471.PubMedPubMedCentralCrossRef
26.
Zhang W, Zhang J, Zhang Z, Guo Y, Wu Y, Wang R, et al. Overexpression of indoleamine 2,3-dioxygenase 1 promotes epithelial-mesenchymal transition by activation of the IL-6/STAT3/PD-L1 pathway in bladder cancer. Transl Oncol. 2019;12(3):485–92.PubMedCrossRef
27.
Karanikas V, Zamanakou M, Kerenidi T, Dahabreh J, Hevas A, Nakou M, et al. Indoleamine 2,3-dioxygenase (IDO) expression in lung cancer. Cancer Biol Ther. 2007;6(8):1258–62.PubMedCrossRef
28.
Su C, Zhang P, Liu J, Cao Y. Erianin inhibits indoleamine 2, 3-dioxygenase-induced tumor angiogenesis. Biomed Pharmacother. 2017;88:521–8.PubMedCrossRef
29.
Wei L, Zhu S, Li M, Li F, Wei F, Liu J, et al. High indoleamine 2,3-dioxygenase is correlated with microvessel density and worse prognosis in breast cancer. Front Immunol. 2018;9:724.PubMedPubMedCentralCrossRef
30.
Pan J, Yuan K, Peng S, Huang Y, Zhang Y, Hu Y, et al. Gene silencing of indoleamine 2,3-dioxygenase hinders tumor growth through angiogenesis inhibition. Int J Oncol. 2017;50(6):2136–44.PubMedCrossRef
31.
Gao Y-F, Peng R-Q, Li J, Ding Y, Zhang X, Wu X-J, et al. The paradoxical patterns of expression of indoleamine 2,3-dioxygenase in colon cancer. J Transl Med. 2009;7(1):71.PubMedPubMedCentralCrossRef
32.
33.
Du L, Xing Z, Tao B, Li T, Yang D, Li W, et al. Both IDO1 and TDO contribute to the malignancy of gliomas via the Kyn-AhR-AQP4 signaling pathway. Signal Transduct Target Ther. 2020;5(1):10.PubMedPubMedCentralCrossRef
34.
Mailankot M, Staniszewska MM, Butler H, Caprara MH, Howell S, Wang B, et al. Indoleamine 2,3-dioxygenase overexpression causes kynurenine-modification of proteins, fiber cell apoptosis and cataract formation in the mouse lens. Lab Invest. 2009;89(5):498–512.PubMedPubMedCentralCrossRef
35.
Zhong W, Gao L, Zhou Z, Lin H, Chen C, Huang P, et al. Indoleamine 2,3-dioxygenase 1 deficiency attenuates CCl4-induced fibrosis through Th17 cells down-regulation and tryptophan 2,3-dioxygenase compensation. Oncotarget. 2017;8(25):40486–500.PubMedPubMedCentralCrossRef
36.
Mohib K, Guan Q, Diao H, Du C, Jevnikar AM. Proapoptotic activity of indoleamine 2,3-dioxygenase expressed in renal tubular epithelial cells. Am J Physiol Renal Physiol. 2007;293(3):F801–12.PubMedCrossRef
37.
Mailankot M, Nagaraj RH. Induction of indoleamine 2,3-dioxygenase by interferon-gamma in human lens epithelial cells: apoptosis through the formation of 3-hydroxykynurenine. Int J Biochem Cell Biol. 2010;42(9):1446–54.PubMedPubMedCentralCrossRef
38.
Eleftheriadis T, Pissas G, Antoniadi G, Tsogka K, Sounidaki M, Liakopoulos V, et al. Indoleamine 2,3-dioxygenase downregulates T-cell receptor complex ζ-chain and c-Myc, and reduces proliferation, lactate dehydrogenase levels and mitochondrial glutaminase in human T-cells. Mol Med Rep. 2016;13(1):925–32.PubMedCrossRef
39.
Sas K, Szabó E, Vécsei L. Mitochondria, oxidative stress and the kynurenine system, with a focus on ageing and neuroprotection. Molecules. 2018;23(1):191.PubMedCentralCrossRef
40.
Abd El-Fattah EE, Saber S, Youssef ME, Eissa H, El-Ahwany E, Amin NA, et al. AKT-AMPKα-mTOR-dependent HIF-1α activation is a new therapeutic target for cancer treatment: a novel approach to repositioning the antidiabetic drug sitagliptin for the management of hepatocellular carcinoma. Front Pharmacol. 2021;12: 720173.PubMedCrossRef
41.
Thaker AI, Rao MS, Bishnupuri KS, Kerr TA, Foster L, Marinshaw JM, et al. IDO1 metabolites activate β-catenin signaling to promote cancer cell proliferation and colon tumorigenesis in mice. Gastroenterology. 2013;145(2):416–25.PubMedCrossRef
42.
Bishnupuri KS, Alvarado DM, Khouri AN, Shabsovich M, Chen B, Dieckgraefe BK, et al. IDO1 and kynurenine pathway metabolites activate PI3K-Akt signaling in the neoplastic colon epithelium to promote cancer cell proliferation and inhibit apoptosis. Can Res. 2019;79(6):1138–50.CrossRef
43.
Serio CD, Cozzi A, Angeli I, Doria L, Micucci I, Pellerito S, et al. Kynurenic acid inhibits the release of the neurotrophic fibroblast growth factor (FGF)-1 and enhances proliferation of glia cells, in vitro. Cell Mol Neurobiol. 2005;25(6):981–93.PubMedCrossRef
44.
45.
Abuelezz SA, Hendawy N, Magdy Y. Targeting oxidative stress, cytokines and serotonin interactions via indoleamine 2, 3 dioxygenase by coenzyme Q10: role in suppressing depressive like behavior in rats. J Neuroimmune Pharmacol. 2017;12(2):277–91.PubMedCrossRef
46.
Grant RS, Naif H, Espinosa M, Kapoor V. IDO induction in IFN-gamma activated astroglia: a role in improving cell viability during oxidative stress. Redox Rep. 2000;5(2–3):101–4.PubMedCrossRef
47.
Wichers MC, Maes M. The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression. J Psychiatry Neurosci. 2004;29(1):11–7.PubMedPubMedCentral
48.
Eleftheriadis T, Pissas G, Liakopoulos V, Stefanidis I. Indoleamine 2, 3-dioxygenase up-regulates hypoxia-inducible factor-1α expression by degrading L-tryptophan but not its activity in human alloreactive T-cells. Iran J Allergy Asthma Immunol. 2018;17(1):56–67.PubMed
49.
Cho YM, Kwon S, Pak YK, Seol HW, Choi YM, Park DJ, et al. Dynamic changes in mitochondrial biogenesis and antioxidant enzymes during the spontaneous differentiation of human embryonic stem cells. Biochem Biophys Res Commun. 2006;348(4):1472–8.PubMedCrossRef
50.
Stapelberg M, Zobalova R, Nguyen MN, Walker T, Stantic M, Goodwin J, et al. Indoleamine-2,3-dioxygenase elevated in tumor-initiating cells is suppressed by mitocans. Free Radical Biol Med. 2014;67:41–50.CrossRef
51.
Low H-Y, Lee Y-C, Lee Y-J, Wang H-L, Chen Y-I, Chien P-J, et al. Reciprocal regulation between indoleamine 2,3-dioxigenase 1 and notch1 involved in radiation response of cervical cancer stem cells. Cancers. 2020;12(6):1547.PubMedCentralCrossRef
52.
53.
Fox E, Oliver T, Rowe M, Thomas S, Zakharia Y, Gilman PB, et al. Indoximod: an immunometabolic adjuvant that empowers T cell activity in cancer. Front Oncol. 2018;8:370.PubMedPubMedCentralCrossRef
54.
Hou D-Y, Muller AJ, Sharma MD, DuHadaway J, Banerjee T, Johnson M, et al. Inhibition of indoleamine 2, 3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Can Res. 2007;67(2):792–801.CrossRef
55.
Yao Y, Liang H, Fang X, Zhang S, Xing Z, Shi L, et al. What is the prospect of indoleamine 2, 3-dioxygenase 1 inhibition in cancer? Extrapolation from the past. J Exp Clin Cancer Res. 2021;40(1):1–14.CrossRef
56.
Mitchell TC, Hamid O, Smith DC, Bauer TM, Wasser JS, Olszanski AJ, et al. Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, open-label phase I/II trial (ECHO-202/KEYNOTE-037). J Clin Oncol. 2018;36(32):3223.PubMedPubMedCentralCrossRef
57.
Rosch JG, Brown AL, DuRoss AN, DuRoss EL, Sahay G, Sun C. Nanoalginates via inverse-micelle synthesis: doxorubicin-encapsulation and breast cancer cytotoxicity. Nanoscale Res Lett. 2018;13(1):1–10.CrossRef
58.
Cook AM, Lesterhuis WJ, Nowak AK, Lake RA. Chemotherapy and immunotherapy: mapping the road ahead. Curr Opin Immunol. 2016;39:23–9.PubMedCrossRef
59.
Meng X, Du G, Ye L, Sun S, Liu Q, Wang H, et al. Combinatorial antitumor effects of indoleamine 2, 3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16–F10 melanoma model. Int J Immunopathol Pharmacol. 2017;30(3):215–26.PubMedPubMedCentralCrossRef
60.
Nelp MT, Kates PA, Hunt JT, Newitt JA, Balog A, Maley D, et al. Immune-modulating enzyme indoleamine 2, 3-dioxygenase is effectively inhibited by targeting its apo-form. Proc Natl Acad Sci. 2018;115(13):3249–54.PubMedPubMedCentralCrossRef
61.
Siu LL, Gelmon K, Chu Q, Pachynski R, Alese O, Basciano P, et al., editors. BMS-986205, an optimized indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitor, is well tolerated with potent pharmacodynamic (PD) activity, alone and in combination with nivolumab (nivo) in advanced cancers in a phase 1/2a trial. Cancer Research; 2017: AMER ASSOC CANCER RESEARCH 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA .
62.
Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, Obaid H, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med. 2011;17(9):1094–100.PubMedPubMedCentralCrossRef
63.
Nakanishi M, Menoret A, Tanaka T, Miyamoto S, Montrose DC, Vella AT, et al. Selective PGE2 suppression inhibits colon carcinogenesis and modifies local mucosal immunity. Cancer Prev Res. 2011;4(8):1198–208.CrossRef
64.
Sharma S, Yang S-C, Zhu L, Reckamp K, Gardner B, Baratelli F, et al. Tumor cyclooxygenase-2/Prostaglandin E2–dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Can Res. 2005;65(12):5211–20.CrossRef
65.
Mukherjee P, Basu GD, Tinder TL, Subramani DB, Bradley JM, Arefayene M, et al. Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition. J Immunol. 2009;182(1):216–24.PubMedCrossRef
66.
Basu GD, Tinder TL, Bradley JM, Tu T, Hattrup CL, Pockaj BA, et al. Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO. J Immunol. 2006;177(4):2391–402.PubMedCrossRef
67.
Iachininoto MG, Nuzzolo ER, Bonanno G, Mariotti A, Procoli A, Locatelli F, et al. Cyclooxygenase-2 (COX-2) inhibition constrains indoleamine 2, 3-dioxygenase 1 (IDO1) activity in acute myeloid leukaemia cells. Molecules. 2013;18(9):10132–45.PubMedPubMedCentralCrossRef
68.
Abd El-Fattah EE, Zakaria AY. Metformin modulate immune fitness in hepatocellular carcinoma: molecular and cellular approach. Int Immunopharmacol. 2022;109: 108889.PubMedCrossRef
69.
Muzik O, Burghardt P, Yi Z, Kumar A, Seyoum B. Successful metformin treatment of insulin resistance is associated with down-regulation of the kynurenine pathway. Biochem Biophys Res Commun. 2017;488(1):29–32.PubMedPubMedCentralCrossRef
70.
Rudzki L, Ostrowska L, Pawlak D, Małus A, Pawlak K, Waszkiewicz N, et al. Probiotic Lactobacillus plantarum 299v decreases kynurenine concentration and improves cognitive functions in patients with major depression: a double-blind, randomized, placebo controlled study. Psychoneuroendocrinology. 2019;100:213–22.PubMedCrossRef
71.
Yamamoto R, Yamamoto Y, Imai S, Fukutomi R, Ozawa Y, Abe M, et al. Effects of various phytochemicals on indoleamine 2, 3-dioxygenase 1 activity: galanal is a novel, competitive inhibitor of the enzyme. PLoS ONE. 2014;9(2): e88789.PubMedPubMedCentralCrossRef
72.
Bai MY, Lovejoy DB, Guillemin GJ, Kozak R, Stone TW, Koola MM. Galantamine-memantine combination and kynurenine pathway enzyme inhibitors in the treatment of neuropsychiatric disorders. Complex Psychiatry. 2021;7(1–2):19–33.PubMedPubMedCentralCrossRef
73.
Naing A, Eder JP, Piha-Paul SA, Gimmi C, Hussey E, Zhang S, et al. Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2, 3-dioxygenase 1 and tryptophan 2, 3-dioxygenase 2, in patients with advanced solid tumors. J Immunother Cancer. 2020;8(2):e000870.PubMedPubMedCentralCrossRef
74.
Matsuno K, Yamazaki H, Isaka Y, Takai K, Unno Y, Ogo N, et al. Novel candesartan derivatives as indoleamine 2, 3-dioxygenase inhibitors. MedChemComm. 2012;3(4):475–9.CrossRef
75.
Brooks AK, Janda TM, Lawson MA, Rytych JL, Smith RA, Ocampo-Solis C, et al. Desipramine decreases expression of human and murine indoleamine-2, 3-dioxygenases. Brain Behav Immun. 2017;62:219–29.PubMedPubMedCentralCrossRef
76.
Thabet NM, Rashed ER, Abdel-Rafei MK, Moustafa EM. Modulation of the nitric oxide/BH4 pathway protects against irradiation-induced neuronal damage. Neurochem Res. 2021;46(7):1641–58.PubMedCrossRef
77.
Agarwal S, Vyas P, Nirwan N, Vohora D. Effect of lacosamide on neuroinflammation-mediated seizures comorbid with depression in C57BL/6 mice–role of kynurenine pathway. Epilepsy Behav. 2021;123: 108262.PubMedCrossRef
78.
Wang C-C, Yang C-J, Wu L-H, Lin H-C, Wen Z-H, Lee C-H. Eicosapentaenoic acid reduces indoleamine 2, 3-dioxygenase 1 expression in tumor cells. Int J Med Sci. 2018;15(12):1296.PubMedPubMedCentralCrossRef
79.
Liu C, Nan Y, Xia Z, Gu K, Chen C, Dong X, et al. Discovery of novel hydroxyamidine derivatives as indoleamine 2, 3-dioxygenase 1 inhibitors with in vivo anti-tumor efficacy. Bioorg Med Chem Lett. 2020;30(8): 127038.PubMedCrossRef
80.
Ogura J, Miyauchi S, Shimono K, Yang S, Gonchigar S, Ganapathy V, et al. Carbidopa is an activator of aryl hydrocarbon receptor with potential for cancer therapy. Biochemical J. 2017;474(20):3391–402.CrossRef
81.
Wang Y, Li C-M, Han R, Wang Z-Z, Gao Y-L, Zhu X-Y, et al. PCC0208009, an indirect IDO1 inhibitor, alleviates neuropathic pain and co-morbidities by regulating synaptic plasticity of ACC and amygdala. Biochem Pharmacol. 2020;177: 113926.PubMedCrossRef
82.
Gostner JM, Ganzera M, Becker K, Geisler S, Schroecksnadel S, Überall F, et al. Lavender oil suppresses indoleamine 2, 3-dioxygenase activity in human PBMC. BMC Complement Altern Med. 2014;14(1):1–10.CrossRef
83.
Al-Hakeim H, Twayej AJ, Al-Dujaili AH, Maes M. Ketoprofen as an add-on treatment to sertraline for drug-Naïve major depressed patients: normalization of plasma levels of Indoleamine-2, 3-dioxygenase in association with pro-inflammatory and immune regulatory cytokines. 2018.
84.
Gostner JM, Schröcksnadel S, Becker K, Jenny M, Schennach H, Überall F, et al. Antimalarial drug chloroquine counteracts activation of indoleamine (2, 3)-dioxygenase activity in human PBMC. FEBS Open Bio. 2012;2:241–5.PubMedPubMedCentralCrossRef
85.
Fung S-PS, Wang H, Tomek P, Squire CJ, Flanagan JU, Palmer BD, et al. Discovery and characterisation of hydrazines as inhibitors of the immune suppressive enzyme, indoleamine 2, 3-dioxygenase 1 (IDO1). Bioorganic & medicinal chemistry. 2013;21(24):7595–603.
86.
Nagy-Grócz G, Laborc KF, Veres G, Bajtai A, Bohár Z, Zádori D, et al. The effect of systemic nitroglycerin administration on the kynurenine pathway in the rat. Front Neurol. 2017;8:278.PubMedPubMedCentralCrossRef
87.
Thomas SR, Mohr D, Stocker R. Nitric oxide inhibits indoleamine 2, 3-dioxygenase activity in interferon-gamma primed mononuclear phagocytes. J Biol Chem. 1994;269(20):14457–64.PubMedCrossRef
88.
Jeong Y-I, Kim SW, Jung ID, Lee JS, Chang JH, Lee C-M, et al. Curcumin suppresses the induction of indoleamine 2, 3-dioxygenase by blocking the Janus-activated kinase-protein kinase Cδ-STAT1 signaling pathway in interferon-γ-stimulated murine dendritic cells. J Biol Chem. 2009;284(6):3700–8.PubMedCrossRef
89.
Kwon M, Ko S-K, Jang M, Kim G-H, Ryoo I-J, Son S, et al. Inhibitory effects of flavonoids isolated from Sophora flavescens on indoleamine 2, 3-dioxygenase 1 activity. J Enzyme Inhib Med Chem. 2019;34(1):1481–8.PubMedPubMedCentralCrossRef
90.
de Bie J, Lim C, Guillemin G. Progesterone alters kynurenine pathway activation in IFN-γ-activated macrophages–relevance for neuroinflammatory diseases. London: SAGE Publications Sage; 2016.
91.
Pertovaara M, Heliövaara M, Raitala A, Oja S, Knekt P, Hurme M. The activity of the immunoregulatory enzyme indoleamine 2, 3-dioxygenase is decreased in smokers. Clin Exp Immunol. 2006;145(3):469–73.PubMedPubMedCentralCrossRef
92.
Song H, Park H, Kim Y-S, Kim KD, Lee H-K, Cho D-H, et al. L-kynurenine-induced apoptosis in human NK cells is mediated by reactive oxygen species. Int Immunopharmacol. 2011;11(8):932–8.PubMedCrossRef
93.
Goettert R, Fidzinski P, Kraus L, Schneider UC, Holtkamp M, Endres M, et al. Lithium inhibits tryptophan catabolism via the inflammation-induced kynurenine pathway in human microglia. bioRxiv. 2020.
94.
Maher AM, Saleh SR, Elguindy NM, Hashem HM, Yacout GA. Exogenous melatonin restrains neuroinflammation in high fat diet induced diabetic rats through attenuating indoleamine 2, 3-dioxygenase 1 expression. Life Sci. 2020;247: 117427.PubMedCrossRef
95.
Koblish HK, Hansbury MJ, Bowman KJ, Yang G, Neilan CL, Haley PJ, et al. Hydroxyamidine inhibitors of indoleamine-2, 3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors. Mol Cancer Ther. 2010;9(2):489–98.PubMedCrossRef
96.
Oxenkrug G, Summergrad P. Benserazide, an inhibitor of peripheral kynurenine metabolism, attenuates olanzapine-induced weight gain, insulin resistance, and dyslipidemia in C57Bl/6j mice. Mol Neurobiol. 2020;57(1):135–8.PubMedCrossRef
97.
Orlikov A, Ryzov I. Caffeine-induced anxiety and increase of kynurenine concentration in plasma of healthy subjects: a pilot study. Biol Psychiat. 1991;29(4):391–6.PubMedCrossRef
98.
Maneechotesuwan K, Ekjiratrakul W, Kasetsinsombat K, Wongkajornsilp A, Barnes PJ. Statins enhance the anti-inflammatory effects of inhaled corticosteroids in asthmatic patients through increased induction of indoleamine 2, 3-dioxygenase. J Allergy Clin Immunol. 2010;126(4):754–62.PubMedCrossRef
99.
Souza LC, de Brito MLO, Jesse CR, Boeira SP, de Gomes MG, Goes ATR, et al. Involvement of kynurenine pathway in depressive-like behaviour induced by nandrolone decanoate in mice. Steroids. 2020;164: 108727.CrossRef
100.
Halaris A, Myint A-M, Savant V, Meresh E, Lim E, Guillemin G, et al. Does escitalopram reduce neurotoxicity in major depression? J Psychiatr Res. 2015;66:118–26.PubMedCrossRef
101.
Ozaki Y, Edelstein MP, Duch DS. The actions of interferon and antiinflammatory agents on induction of indoleamine 2, 3-dioxygenase in human peripheral blood monocytes. Biochem Biophys Res Commun. 1987;144(3):1147–53.PubMedCrossRef
102.
Maciejak P, Szyndler J, Turzyńska D, Sobolewska A, Kołosowska K, Lehner M, et al. The kynurenine pathway: a missing piece in the puzzle of valproate action? Neuroscience. 2013;234:135–45.PubMedCrossRef
103.
Metadata
Title
IDO/kynurenine pathway in cancer: possible therapeutic approaches
Author
Eslam E. Abd El-Fattah
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2022
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-022-03554-w

Other articles of this Issue 1/2022

Journal of Translational Medicine 1/2022 Go to the issue

Methodology

Mini-XT, a miniaturized tagmentation-based protocol for efficient sequencing of SARS-CoV-2

Research

Identifying causal genes for stroke via integrating the proteome and transcriptome from brain and blood

Review

Exhaustion of CAR T cells: potential causes and solutions

Research

Identification of DNA methylation-regulated differentially expressed genes in RA by integrated analysis of DNA methylation and RNA-Seq data

Research

Atrial myocyte-derived exosomal microRNA contributes to atrial fibrosis in atrial fibrillation

Research

Lenvatinib inhibits the growth of gastric cancer patient-derived xenografts generated from a heterogeneous population
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits